← Back to 25B-NBOMe

25B-NBOMe Stats & Data

Psychedelic Research-chemical

25b

NPS DataHub

MW380.28

FormulaC18H22BrNO3

CAS1026511-90-9

IUPAC2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine

SMILESCOc1ccccc1CNCCc1cc(OC)c(Br)cc1OC

InChIKeySUXGNJVVBGJEFB-UHFFFAOYSA-N

Phenethylamines; 2020/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2021/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2022/1. Von 2-Phenethylamin abgeleitete Verbindungen

Chemical Class Phenethylamine

Psychoactive Class Psychedelic

History & Culture

25B-NBOMe was first described in the scientific literature by Ralf Heim and colleagues at the Free University of Berlin, with initial findings presented in conference abstracts as early as 1999. The compound was subsequently characterized in more detail through continued research at the institution in the early 2000s. The substance had no documented history of recreational human use until 2010, when it first emerged on the online research chemical market. Its high potency, allowing active doses to be applied to blotter paper similar to LSD, contributed to its rapid adoption among those seeking novel psychoactive substances. This blotter form also led to instances where users mistook 25B-NBOMe for LSD. Independent of its recreational emergence, researchers in Copenhagen developed a carbon-11 labeled version of the compound, designated [11C]Cimbi-36, for use as a positron emission tomography radiotracer. This radioligand was investigated as a potential functional marker of serotonin 2A receptors and as an indicator of serotonin release in living subjects. The radiolabeled compound has since undergone clinical trials for use as a neuroimaging tool in humans.

Subjective Effect Notes

cognitive: The head space of 25B-NBOMe is described by many as remarkably light and underwhelming in comparison to the classical psychedelics. It is not uncommon for people to report feeling that their thought stream has maintained general normality in its specific style throughout low to moderate dosages. At high dosages however, mild to overwhelming cognitive alterations become present.

Effect Profile

Curated + 40 Reports

Psychedelic 8.8

Strong visuals, headspace, auditory effects, and body load

Visual Intensity×3

10105.5

Headspace Depth×3

10104.9

Auditory Effects×1

10102.9

Body Load / Somatic Effects×1

10102.9

Catalog Erowid BlueLight

Based on reports from:

Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki 25B-NBOMe

Duration Timeline

Bluelight

Onset Comeup Peak Offset After Effects

Insufflated

1-4 minutes

8.0-12.0 hours

2.0-6.0 hours

Total: 8-12 hours

Sublingual

18-42 minutes

30 minutes - 1.5 hours

4-6 hours

2-4 hours

2-6 hours

Total: 8-12 hours

Community Effects

TripSit

Positive

visual enhancement

Negative

seizures

Tolerance & Pharmacokinetics

drugs.wiki

Tolerance Decay

Full tolerance 1h Half tolerance 10d Baseline ~14d

Cross-Tolerances

LSD

60% ●○○

Psilocybin

65% ●○○

Psilocin

65% ●○○

Mescaline

85% ●○○

DMT

65% ●○○

5-MeO-DMT

65% ●○○

2C-B

85% ●○○

2C-E

85% ●○○

Experience Report Analysis

Erowid BlueLight

33 Reports

2012–2016 Date Range

31 With Age Data

30 Effects Detected

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Erowid + Bluelight

Effects aggregated from 40 experience reports (33 Erowid + 7 Bluelight)

40 Reports

71 Effects Detected

29 Positive

29 Adverse

13 Neutral

Effect Sentiment Distribution

Confidence Distribution

Positive Effects 29

Color Enhancement 55.0% 85%

Music Enhancement 47.5% 90%

Stimulation 47.5% 80%

Entity Imagery 42.9% 77%

Joy 42.9% 83%

Euphoria 42.5% 90%

Tactile Enhancement 39.4% 70%

Empathy 32.5% 75%

Focus Enhancement 32.5% 70%

Introspection 30.0% 80%

Geometric Imagery 28.6% 85%

Pattern Recognition Enhancement 28.6% 75%

Open-Eye Visuals 28.6% 85%

Visual Trails 14.3% 70%

Gratitude 14.3% 85%

Contentment 14.3% 80%

Drowsiness 14.3% 80%

Insight 14.3% 80%

Sociability Enhancement 14.3% 75%

Brightness Enhancement 14.3% 80%

Adverse Effects 29

Anxiety 62.5% 88%

Confusion 45.0% 85%

Nausea 30.3% 70%

Muscle Tension 30.0% 75%

Dizziness 28.6% 85%

Panic 28.6% 88%

Fear 28.6% 90%

Body Temperature Change 28.6% 78%

Thought Loops 25.0% 88%

Stomach Cramps 14.3% 75%

Pressure 14.3% 80%

Morphing 14.3% 85%

Motor Suppression 14.3% 75%

Field Narrowing 14.3% 75%

Auditory Delay 14.3% 70%

Body Distortion 14.3% 80%

Communication Suppression 14.3% 80%

Temporal Disorientation 14.3% 75%

Insomnia 14.3% 75%

Body Load 14.3% 80%

Real-World Dose Distribution

62K Doses

From 35 individual dose entries

Sublingual (n=13)

Median: 0.6mg 25th: 0.4mg 75th: 1.0mg 90th: 1.96mg

mg/kg median: 0.01 mg/kg 75th: 0.016

Form / Preparation

Most common forms and preparations reported

Body-Weight Dosing

Dose relative to body weight from reports with weight data

Median: 0.013 mg/kg IQR: 0.01–0.022 mg/kg n=9

Redose Patterns

Redosing behavior across 31 reports

16.1% Redosed

1.2 Avg Doses

Read full reports on Erowid →

Legal Status

Country	Status	Notes
Austria	Illegal (SMG)	Prohibited under the Suchtmittelgesetz (Narcotic Substances Act) since June 26, 2019. Possession, production, and sale are illegal.
Brazil	Illegal (Portaria SVS/MS nº 344)	Listed as a controlled substance under Portaria SVS/MS nº 344. Possession, production, and sale are prohibited.
Canada	Schedule III (CDSA)	Controlled under Schedule III of the Controlled Drugs and Substances Act as of October 31, 2016. Classified as a derivative of 2,5-dimethoxyphenethylamine.
China	Controlled substance	Designated as a controlled substance as of October 2015 under national drug control regulations.
Czech Republic	Banned	Prohibited substance under Czech drug legislation.
Finland	Scheduled narcotic	Listed in the government decree on substances, preparations, and plants considered to be narcotic drugs.
Germany	Anlage I BtMG	Controlled under Anlage I of the Betäubungsmittelgesetz (Narcotics Act) since December 13, 2014. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing without license are prohibited.
Italy	Schedule I	Classified as a Schedule 1 controlled substance under Italian drug legislation.
Japan	Narcotic	Designated as a narcotic drug under Japanese law, effective November 1, 2015.
Latvia	Schedule I	Classified as a Schedule I controlled substance under Latvian drug control legislation.
New Zealand	Schedule 2	Controlled as a Schedule 2 substance under the Misuse of Drugs Act.
Russia	Banned	Prohibited as a narcotic drug since May 5, 2015 under Russian federal drug control legislation.
Sweden	Schedule I	Added to Schedule I (substances normally without medical use) as of August 1, 2013, published by the Medical Products Agency in regulation LVFS 2013:15.
Switzerland	Controlled (Verzeichnis D)	Specifically named as a controlled substance under Verzeichnis D of Swiss narcotics legislation.
Turkey	Illegal	Classified as a controlled drug. Possession, production, supply, and import are prohibited.
United Kingdom	Class A	Controlled as a Class A substance under the Misuse of Drugs Act 1971 through the N-benzylphenethylamine catch-all clause. Class A carries the most severe penalties for possession and supply.
United States	Schedule I	Placed in Schedule I of the Controlled Substances Act by the DEA in November 2013 using emergency scheduling powers, alongside 25I-NBOMe and 25C-NBOMe. Manufacturing, purchase, possession, processing, and distribution are prohibited.

← Back to 25B-NBOMe